Search
InflaRx NV
IFRXAdd to Watchlist
2.240USD
-0.090-3.86%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
161.94MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.86%
5 Days
+16.67%
1 Month
+12.00%
6 Months
+105.50%
Year to Date
+121.78%
1 Year
+179.16%
Key Figures
2.420Open
2.480High
777.47KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.08%Turnover Ratio
2.330Prev. Close
2.200Low
1.20MTurnover
LossP/E Static
3.74P/B
0.00%Div Yield TTM
-63.16%ROA
2.94952wk High
0.53Volume Ratio
-46.06MNet Profit
72.29MShares
-0.5404EPS TTM
2.44Beta
-79.94%ROE
0.74152wk Low
12.02%Amplitude
-24677.94%Gross Margin
161.94MMarket Cap
2.74Reward/Risk
6.01%Risk Rate
TradingKey Stock Score of InflaRx NV
Currency: USD Updated: 2026-07-02Key Insights
InflaRx NV's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 124 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
InflaRx NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
InflaRx NV Highlights
StrengthsRisks
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Growing
The company is in a growing phase, with the latest annual income totaling USD 33.99K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 33.99K.
Undervalued
The company’s latest PE is -4.15, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 19.59M shares, decreasing 19.00% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.58.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
8.000
Target Price
+243.35%
Upside Space
InflaRx NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
InflaRx NV Info
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Ticker SymbolIFRX
CompanyInflaRx NV
CEORiedemann (Niels C)
Websitehttps://www.inflarx.de/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of InflaRx NV (IFRX)?
The current price of InflaRx NV (IFRX) is 2.24.
What is the symbol of InflaRx NV?
The ticker symbol of InflaRx NV is IFRX.
What is the 52-week high of InflaRx NV?
The 52-week high of InflaRx NV is 2.95.
What is the 52-week low of InflaRx NV?
The 52-week low of InflaRx NV is 0.74.
What is the market capitalization of InflaRx NV?
The market capitalization of InflaRx NV is 161.94M.
Is InflaRx NV (IFRX) currently rated as Buy, Hold, or Sell?
According to analysts, InflaRx NV (IFRX) has an overall rating of Buy, with a price target of 8.00.
What is the Earnings Per Share (EPS TTM) of InflaRx NV (IFRX)?
The Earnings Per Share (EPS TTM) of InflaRx NV (IFRX) is -0.80.